Fish oil inhibits photochemically induced thrombosis in the guinea pig in a dose dependent manner

Jerling, Johann C.; Curiel-Martos, Alexandra; Kroner, Christine; Kloots, Willem

doi:10.1016/j.thromres.2003.08.001

Cited by 5 publications

(7 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The secondary nature of this end point and the small total number of MI make interpretations slightly speculative; nevertheless, there are several possible mechanisms that might explain such an effect. First, an antithrombotic effect of n-3 PUFA could be of importance, and previous animal studies showed that n-3 PUFA inhibit thrombus formation (30). Although in human trials large doses of n-3 PUFA have been used to achieve antithrombotic effects, in daily clinic, the antithrombotic effect of n-3 PUFA has not been documented convincingly (16).…”

Section: Discussionmentioning

confidence: 99%

N-3 Fatty Acids as Secondary Prevention against Cardiovascular Events in Patients Who Undergo Chronic Hemodialysis

Svensson

Schmidt

Jørgensen

et al. 2006

Clinical Journal of the American Society of Nephrology

127

View full text Add to dashboard Cite

Patients who are treated with chronic hemodialysis (HD) experience premature cardiovascular disease and an increased mortality. N-3 polyunsaturated fatty acids (PUFA) may be effective in the secondary prevention of cardiovascular disease, but the effects of n-3 PUFA has not previously been examined in HD patients. It was hypothesized that secondary prevention with n-3 PUFA would reduce the number of cardiovascular events and death in patients who are treated with chronic HD. A randomized, double-blind, placebo-controlled intervention trial compared the effect of n-3 PUFA and a control treatment as secondary prevention of cardiovascular events in HD patients. The primary outcome was a composite of total cardiovascular events and death. A total of 206 patients were randomly assigned to treatment with n-3 PUFA or control treatment and followed for 2 yr or until reaching a predefined end point. During the trial, 121 (59%) of 206 patients reached a primary end point. N-3 PUFA had no significant effect on the primary composite end point of cardiovascular events and death (62 versus 59; NS). In the n-3 PUFA group, a significant reduction was seen in the number of myocardial infarctions (four versus 13; P ‫؍‬ 0.036). This trial was limited by a relatively small number of patients and a large number of withdrawals. However, it is concluded that treatment with n-3 PUFA did not reduce the total number of cardiovascular events and death in this high-risk population. N-3 PUFA significantly reduced the number of myocardial infarctions as a secondary outcome, a finding that might be of clinical interest.Clin J Am Soc Nephrol 1: 780 -786, 2006. doi: 10.2215/CJN.00630206 P atients who are treated with chronic hemodialysis (HD) have a high incidence of cardiovascular disease (CVD) and an increased premature mortality (1,2). Traditional risk factors of CVD are frequent in patients with kidney disease (3); in addition, the uremic milieu results in inflammation (4), specific alterations in lipid metabolism (5), and accumulation of uremic toxins (6), which may contribute to the high risk for CVD. During recent years, there has been focus on the need for intervention trials to prevent CVD and reduce mortality in this high-risk population (7).Evidence exists from both epidemiologic (8) and interventional studies (9) that n-3 polyunsaturated fatty acids (PUFA) might be effective as secondary prevention of CVD and possibly prevent sudden cardiac death (10). However, a recent Cochrane analysis concluded that there is no clear evidence that n-3 PUFA reduce cardiovascular mortality and that there is a need for additional intervention studies in this area of research (11). The possible mechanisms of n-3 PUFA include a lipidlowering effect, with a reduction in plasma triglycerides (12) and a mild antihypertensive effect (13). Several other possible protective mechanisms of n-3 PUFA also have been reported, such as anti-inflammatory (14), antiatherosclerotic (15), antithrombotic (16), and antiarrhythmic (17). The effect of n-3 PUFA on CVD has ...

show abstract

Section: Discussionmentioning

confidence: 99%

N-3 Fatty Acids as Secondary Prevention against Cardiovascular Events in Patients Who Undergo Chronic Hemodialysis

Svensson

Schmidt

Jørgensen

et al. 2006

Clinical Journal of the American Society of Nephrology

127

View full text Add to dashboard Cite

show abstract

“…46,47 Such changes have been attributed to a reduced decrease of thromboxane A 2 and an increase of the nonaggregating thromboxane A 3 . 48…”

Section: N-3 and Platelet Functionmentioning

confidence: 99%

Nutrition, Supplements, and Vitamins in Platelet Function and Bleeding

2010

View full text Add to dashboard Cite

“…Rats were subjected to astandard protocol for measurement of photochemically induced thrombosis (27). Briefly, the rats were anaesthetized with ketamine and domitor (intramuscular, 40 and 500 mg kg -1 body weight, respectively), and fixedonaheating pada t3 6°C.…”

Section: In Vivo Thrombusformationmentioning

confidence: 99%

“…Thrombusformation wasevaluatedbymeasuring the time to vascularocclusion and the area under the curve of blood flow, calculated over 30 min. Thelattergives an indication of the overallb lood flow response during the whole measurement period (27).…”

Section: In Vivo Thrombusformationmentioning

confidence: 99%

Regulation of tissue factor-induced coagulation and platelet aggregation in flowing whole blood

Kuijpers

Nieuwenhuys²,

Feijge³

et al. 2005

Thromb Haemost

Self Cite

View full text Add to dashboard Cite

Photochemically induced thrombosis (a thrombin-dependent process) was measured in rats treated with moderate doses of anticoagulants, but which appeared to be unchanged. We considered the possibility that platelet-inhibiting agents, which also indirectly inhibit coagulation, would act as more potent antithrombotic agents. Inhibitors used as such were prostaglandin E1 (PGE1), which elevates cyclic AMP levels, and the P2Y12 ADP-receptor antagonist, AR-C69931MX. Effects of these agents were investigated in an ex vivo model system, in which whole blood under coagulant conditions was perfused over fibrinogen at defined wall shear rate. Perfusion of blood (rat or human) in the presence of tissue factor resulted in deposition of activated platelets and subsequent aggregate formation, along with exposure of procoagulant phosphatidylserine (PS) on the platelet surface and formation of fibrin fibers. In the presence of PGE1 aggregation was completely inhibited, but platelet adhesion and PS exposure were only party reduced, while fibrin formation was hardly affected. Treatment with AR-C69931MX caused similar, but less complete effects. These results indicate that in tissue factor-triggered blood under conditions of flow: (i) the platelet procoagulant response is independent of aggregate formation; (ii) the platelet-inhibiting effect of PGE1 and AR-C69931MX is sufficient to suppress aggregation, but not platelet adhesion and coagulation. These platelet inhibitors thus maintain their aggregation-inhibiting effect at sites of thrombin formation.

show abstract

Fish oil inhibits photochemically induced thrombosis in the guinea pig in a dose dependent manner

Cited by 5 publications

References 28 publications

N-3 Fatty Acids as Secondary Prevention against Cardiovascular Events in Patients Who Undergo Chronic Hemodialysis

N-3 Fatty Acids as Secondary Prevention against Cardiovascular Events in Patients Who Undergo Chronic Hemodialysis

Nutrition, Supplements, and Vitamins in Platelet Function and Bleeding

Regulation of tissue factor-induced coagulation and platelet aggregation in flowing whole blood

Contact Info

Product

Resources

About